1-(3-fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea

ID: ALA5172091

Chembl Id: CHEMBL5172091

Cas Number: 1370466-81-1

PubChem CID: 66981446

Max Phase: Preclinical

Molecular Formula: C26H19F4N5O2

Molecular Weight: 509.46

Associated Items:

Names and Identifiers

Canonical SMILES:  Cc1cnc(-c2ccc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3F)c3c2C(=O)NC3)[nH]1

Standard InChI:  InChI=1S/C26H19F4N5O2/c1-13-11-31-23(33-13)19-8-7-17(20-12-32-24(36)22(19)20)18-6-5-16(10-21(18)27)35-25(37)34-15-4-2-3-14(9-15)26(28,29)30/h2-11H,12H2,1H3,(H,31,33)(H,32,36)(H2,34,35,37)

Standard InChI Key:  BOLRZWTVMUHQQU-UHFFFAOYSA-N

Associated Targets(Human)

MV4-11 (7307 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MOLM-13 (2241 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
FLT3 Tclin Tyrosine-protein kinase receptor FLT3 (13481 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

BaF3 (4657 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 509.46Molecular Weight (Monoisotopic): 509.1475AlogP: 6.10#Rotatable Bonds: 4
Polar Surface Area: 98.91Molecular Species: NEUTRALHBA: 3HBD: 4
#RO5 Violations: 2HBA (Lipinski): 7HBD (Lipinski): 4#RO5 Violations (Lipinski): 2
CX Acidic pKa: 11.26CX Basic pKa: 6.54CX LogP: 4.72CX LogD: 4.67
Aromatic Rings: 4Heavy Atoms: 37QED Weighted: 0.25Np Likeness Score: -0.94

References

1. Ran F, Liu Y, Xu Z, Meng C, Yang D, Qian J, Deng X, Zhang Y, Ling Y..  (2022)  Recent development of BTK-based dual inhibitors in the treatment of cancers.,  233  [PMID:35247756] [10.1016/j.ejmech.2022.114232]
2. Liu XJ, Xu-Liu, Pang XJ, -Ying Yuan X, Yu GX, Li YR, Guan YF, Zhang YB, Song J, Zhang QR, Zhang SY..  (2021)  Progress in the development of small molecular inhibitors of the Bruton's tyrosine kinase (BTK) as a promising cancer therapy.,  47  [PMID:34479103] [10.1016/j.bmc.2021.116358]

Source